Sino-US Pficker Pharmaceuticals Announces R&D Breakthrough
This article was originally published in PharmAsia News
Sino-US Pficker Pharmaceuticals recently announced that its R&D team, the pioneer of oxidative stress window phase theory, has applied the intervention theory in its industrial process. Company officials said the oxidative stress window phase theory has been verified to make disease prevention and treatment safer and more intuitive. As a technology-driven pharmaceutical corporation, Sino-US Pficker owns the worldwide intellectual property of three new drugs' developing techniques. Its "rinse-free" hand detergent, which can kill virus and bacteria quickly and effectively, is in the final stages of approval and will be launched soon. (Click here for more - Chinese Language)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.